- Home
- GOSS vs ANVS Comparison
GOSS vs ANVS Comparison
Compare GOSS & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOSS | ANVS |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.2M | 111.3M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GOSS | ANVS |
|---|---|---|
| Price | $0.43 | $2.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $4.91 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 25.1M | 337.5K |
| Earning Date | 03-17-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,471,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.33 | $1.11 |
| 52 Week High | $3.87 | $5.50 |
Technical Indicators
Market Signals| Indicator | GOSS | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 23.44 | 44.59 |
| Support Level | $0.33 | $2.29 |
| Resistance Level | $0.60 | $2.63 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 22.86 | 10.49 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.